54.86 
0.30(0.55%) May 24, 4:02PM EDT|After Hours
:
54.68 0.18 (0.32%) May 24, 4:54PM EDT
| Prev Close: | 54.56 |
|---|
| Open: | 54.80 |
|---|
| Bid: | 53.96 x 200 |
|---|
| Ask: | 69.99 x 100 |
|---|
| 1y Target Est: | 68.53 |
|---|
| Beta: | 1.07 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 54.36 - 54.88 |
|---|
| 52wk Range: | 33.03 - 55.86 |
|---|
| Volume: | 1,340,738 |
|---|
| Avg Vol (3m): | 2,435,270 |
|---|
| Market Cap: | 145.20B |
|---|
| P/E (ttm): | 27.04 |
|---|
| EPS (ttm): | 2.03 |
|---|
| Div & Yield: | 1.30 (2.40%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Encouraging News for Peregrine PharmaZacks(Fri, May 24)
- The Coming Diabetes Warsat Motley Fool(Thu, May 23)
- 4 Contagion Playsat Forbes(Thu, May 23)
- Sanofi Stock Buy Recommendation Reiterated (SNY)at TheStreet(Thu, May 23)
- Merrimack completes enrollement in a Phase 2 study of MM-121 with Sanofiat theflyonthewall.com(Thu, May 23)
- Another Multiple Sclerosis Winner for Biogenat Motley Fool(Wed, May 22)
- Sanofi/REGN's Dupilumab Data PublishedZacks(Wed, May 22)
- Regeneron and Sanofi: An Unstoppable Biotech Duo?at Motley Fool(Tue, May 21)
- New Drug May Help Some Asthmatics, Study Findsat New York Times(Tue, May 21)
- Elan Continues To Make Baffling Strategic Decisionat Investopedia(Tue, May 21)
- Will Influenza A H7N9 Generate Opportunities For Pharma?at Seeking Alpha(Tue, May 21)
- New Asthma Drug Generates Excitement For Patients -- And Its Makerat Forbes(Tue, May 21)
- Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of MedicinePR Newswire(Tue, May 21)
- Sanofi Relies on Axway to Future-Proof their Infrastructure and Reduce Operational Costs through Global ConsolidationBusiness Wire(Tue, May 21)
- Sanofi (SNY): Today's Featured Drugs Laggardat TheStreet(Mon, May 20)
Key Statistics
| Forward P/E (1 yr): | 12.79 |
|---|
| P/S (ttm): | 3.17 |
|---|
| Ex-Dividend Date: | 06-May-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 3.76 |
|---|
| Quarterly EPS Est
(Mar-13)
: | N/A |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | 2.07 |
|---|
Business Summary
Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments.
View More